Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors

Written by Customer Service on January 31, 2022. Posted in Public Companies.

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors (“Board”). “Jon is a well-respected physician-scientist and drug development expert. With his diverse background, he has driven numerous clinical stage immuno-oncology development portfolios,” said Alan Fuhrman, Interim CEO and President of Checkmate. “We are thrilled to strengthen Checkmate’s Board by leveraging Jon’s broad experience across academia, government and the biopharmaceutical industry, as well as his lifelong career dedication to improving the lives of patients with cancer.” Dr....

Xometry Announces Unaudited Preliminary Fourth Quarter 2021 Results

Written by Customer Service on January 31, 2022. Posted in Public Companies.

ROCKVILLE, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) — Xometry (NASDAQ:XMTR), the AI-driven digital marketplace that connects enterprise buyers with manufacturers globally, today announced estimated unaudited preliminary revenue and gross profit margin for the three months ended December 31, 2021. Preliminary total revenue for the fourth quarter 2021 is expected to be in the range of $65.5 million to $67.5 million. Preliminary total revenue includes revenue from Thomas Publishing Company (“Thomas”) from the date of acquisition on December 9, 2021, which is expected to be in the range of $3.5 million to $4.5 million. Excluding Thomas, preliminary Xometry revenue for the fourth quarter 2021 is expected to be in the range of $62.0 million to $63.0 million, compared to $38.0 million for the fourth quarter 2020. This represents year-over-year...

AmmPower Corp. Provides Additional Information Regarding Letter of Intent to Develop Ammonia Production Facility with Port of South Louisiana – Largest Tonnage Port in the Western Hemisphere

Written by Customer Service on January 31, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, Jan. 31, 2022 (GLOBE NEWSWIRE) — AmmPower Corp. (CSE: AMMP) (OTCQB: AMMPF) (FSE: 601A) (the “Company” or “AmmPower”) is pleased to clarify and provide additional information in relation to certain disclosure contained in its press release issued earlier today. The Company notes that it has signed a Letter of Intent (“LOI”) with the Port of South Louisiana (“PoSL”), pursuant to which AmmPower and PoSL will jointly explore the feasibility of developing a green hydrogen/ammonia facility at the PoSL (the “Potential Project”). PoSL is the largest tonnage port in the Western Hemisphere, servicing over $57 Billion in Exports, and $18 Billion in imports every year. Stretching 54 miles along the Mississippi River, PoSL is a vital port to the United States, and ranks first in total domestic trade...

DHT Holdings, Inc. to announce fourth quarter 2021 results Monday February 7, 2022

Written by Customer Service on January 31, 2022. Posted in Public Companies.

HAMILTON, BERMUDA, January 31, 2022 – DHT Holdings, Inc. (NYSE: DHT or the “Company”) will release its fourth quarter 2021 results after market close on Monday February 7, 2022. The Company will host a conference call and webcast, which will include a slide presentation at 08:00 a.m. EST/14:00 CET on Tuesday February 8, 2022 to discuss the results for the quarter. The conference call may be accessed by calling +1 646 741 3167 within the United States, +47 21 56 30 15 within Norway and +44 (0) 207 192 8338 for international callers. The confirmation code is “6173527”. The webcast which will include a slide presentation will be available on the following link: https://edge.media-server.com/mmc/p/j628874j and can also be accessed in the Investor Relations section on DHT’s website at www.dhtankers.com. An audio replay of the conference...

ARMOUR Residential REIT, Inc. Announces February 2022 Dividend Rate per Common Share

Written by Customer Service on January 31, 2022. Posted in Dividend Reports And Estimates.

VERO BEACH, Florida, Jan. 31, 2022 (GLOBE NEWSWIRE) — ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced the February 2022 cash dividend for the Company’s Common Stock. February 2022 Common Stock Dividend Information Month Dividend Holder of Record Date Payment Date February 2022 $0.10 February 15, 2022 February 28, 2022 Certain Tax Matters ARMOUR has elected to be taxed as a real estate investment trust (“REIT”) for U.S. Federal income tax purposes. In order to maintain this tax status, ARMOUR is required to timely distribute substantially all of its ordinary REIT taxable income. Dividends paid in excess of current tax earnings and profits for the year will generally not be taxable to common stockholders. Actual dividends are determined at the discretion of...

Woodward Increases Dividend by 17 Percent

Written by Customer Service on January 31, 2022. Posted in Dividend Reports And Estimates.

FORT COLLINS, Colo., Jan. 31, 2022 (GLOBE NEWSWIRE) — Woodward, Inc. (NASDAQ: WWD) today announced that its Board of Directors approved a dividend of $0.19 per share, up from the prior quarter’s dividend of $0.1625 per share. The dividend will be payable on March 7, 2022, for stockholders of record as of February 21, 2022. About Woodward, Inc. Woodward is the global leader in the design, manufacturing, and service of energy conversion and control solutions for the aerospace and industrial equipment markets. Together with our customers, we are enabling the path to a cleaner, decarbonized world. Our innovative fluid, combustion, electrical, propulsion and motion control systems perform in some of the world’s harshest environments. Woodward is a global company headquartered in Fort Collins, Colorado, USA. Visit our website at www.woodward.com. Notice...

Celyad Oncology Announces February 2022 Conference Schedule

Written by Customer Service on January 31, 2022. Posted in Public Companies.

MONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in February 2022: Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022Dates: Monday, February 14 to Friday, February 18, 2022Presentation: February 18, 8 a.m. ET / 2 p.m. CETPresenter: Filippo Petti, CEO Webcast: A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website. About Celyad Oncology SA Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen...

Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

Written by Customer Service on January 31, 2022. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the appointment of Gary Lee, Ph.D., as Chief Scientific Officer. A veteran biotech leader with more than a decade of experience heading translational cell and gene therapy programs, Dr. Lee will set and oversee the company’s research strategy and advance its research pipeline. “We are thrilled to welcome Gary and his scientific expertise in translational cell therapy to the Lyell team,” said Liz Homans, Chief Executive Officer of Lyell. “Beyond his exceptional scientific talent, Gary brings tremendous leadership and strategic planning capabilities to our team. As we become a clinical-stage company, his appointment...

Parsons Building the Future of Industrial Cities at OXAGON

Written by Customer Service on January 31, 2022. Posted in Public Companies.

CENTREVILLE, Va., Jan. 31, 2022 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) today announced its selection by NEOM Company to provide project management support in building OXAGON – a reimagined industrial city. NEOM was created by Saudi Arabia’s Public Investment Fund (PIF) as part of the Kingdom’s Vision 2030 to redefine urban living. OXAGON, as one of NEOM’s new regions, will represent the future of Industrial Cities. Parsons will work closely with NEOM and OXAGON to deliver project management, technical, commercial and construction management services to deliver a fully functioning industrial city. “Saudi Arabia’s leadership is driving the future vision for NEOM, and we are honored to support them in building the pioneering cognitive city of OXAGON, which will become home for some of the most forward thinking and visionary...

Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day

Written by Customer Service on January 31, 2022. Posted in Public Companies.

Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable BETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today announced additional details on its R&D Day being held virtually on Friday, February 4, 2022 from 10:00 am – 12:00 pm Eastern Time. The R&D Day Event, entitled “Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable” will feature presentations from several Key Opinion Leaders (KOLs): Zoe Cournia, PhD (Biomedical Research Foundation Academy of Athens) will discuss the role of...

Day: January 31, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice